ALBO - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Albireo Pharma First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that this conference is being recorded. I would now turn the call over to your host, Hans Vitzthum, Managing Director of LifeSci Advisors. you. Thank

begin. may You

Hans Vitzthum

the and company's This everyone. press afternoon, business is results its operator, XXXX. March joining press at This release you www.albireopharma.com. today's recent release for financial and call. Albireo via accomplishments quarter good you, ended Thank XX, the afternoon, accessible for highlighting first website Thank issued a

Private and risks Before various subsequent represent Securities subject These accessed made statements. filings. statements our of We Form views most regarding forward-looking those today of these representing may or proceeding, we filings include of of website being described Act our and any statements recent obligation would Reform in views the to due including as Actual are today, like company's Litigation from XX, be the of and to may expectations. plans XXXX, dates. at XX-K note under forward-looking our are to statements differ materially factors, the to as that be on Any and management's our comments they undertake results publicly section These should upon www.albireopharma.com the section Risk subsequent not the Investors important and uncertainties. various XXXX, relied as no May update website. can SEC's SEC Factors

and Albireo's Now, Officer. it is my Ron? pleasure call over Chief Executive President to Ron Cooper, turn to the

Ron Cooper

me our Mattsson, Harford, R&D. today Thank you, Chief Simon With Jan and and Hans, Pamela and Officer; Dr. Officer Chief Head are us. everybody, thank Chief joining Commercial Financial you, our Scientific for of Officer; Stephenson,

on look them for and our to you during the related wish Bylvay to slides metrics at that note please if begin, uptake available are website, we revenue call. our Before key

are the excellent on a pleased stage, cash of to base. of One, of launch studies, and through the on on pipeline delivered $XXX.X process, with continuing early execution are Bylvay cholestatic we're There Atresia; fronts all in two, on positive strong three gold still and both build with development use that three, Phase quarter products we're the additional growth in Biliary million launch early-stage position sheet. very our business III Bylvay our At a of we're diseases Alagille While this commercial launch syndrome adult the our in development reported have in important in we clinical another expanding for and Bylvay today, of viral drivers and PFIC; track Albireo. am milestones I the strong rapidly global for balance liver the and emerging diseases. standard

a are milestone looking bright readouts. We to forward multiple future with

of to let Now talk in the me it Pamela? turn global about launch Bylvay to over Pamela PFIC.

Pamela Stephenson

and net patients with $X.X with product this have response how are the category. providers disease really the our worldwide of reported I in international. QX, patients I'm with million care that reach takeaways continues through and on be illustrate growth. into progress setting you give insights million for with will measure future on Starting total are $X.X $X.X as to total who up available will ourselves Bylvay. and X,XXX key in continue Global five rare estimated planned, us the the The U.S. pull-through going demand and from delivering for million key impact launches payers treatment To growth, to the positive. in health that launch, revenue. made a is we pleased to in launch and Ron. the take the We and we European strategy we metrics global for PFIC Thanks, are the we

inventory from continued to demand in a grow. was impacted the prior by drawdown revenue underlying While of quarter, U.S. the reported

the as outstanding Germany, response we this market demand U.S. high of to by attribute later penetration due are soon to We be solid the percentage month. physician and Bylvay growth represents to and increase in excellent U.K. international So performance this launch seeing date the payer the dispenses. in a in to our sales experience performance an Bylvay followed growing with

QX greater than of in were patients insured reimbursed. fact, In XX% U.S.

are our to positive plants all patients than We coverage fail, most due Cigna Anthem, payers, days. United is which of with Aetna, decisions for including also less major across very pleased from U.S. all XX strong is and the This Healthcare. and time to coverage

through of access more outcome reimbursement In we increased and with have in we eagerly coming and the pleased addition, submissions in await recommendation are are expect and improvements Europe, coverage and positive XX off nice State pricing policies. know months. In building the Medicaid the to

Moving to generated. These new are prescriptions. the prescriptions number the total of new

reported, we X we've in prescriptions disease had the As patient new rare months launch. XXX of this first

are successfully prescribed As rare patient with of new These that our patients continuing the XX captured drug in Slide deck, trial building overview expect for patients annuity presented recently starts the we patients increase. that are have Bylvay. in and wave patients disease. diagnosed are you'd a corporate quickly first shows or What or in this the a is waiting growth shows we who to option

are now are focusing their doctor of but seemingly couple times stable in care of We patients year. not capturing are crisis. on who wave a patients second that under a They visiting

we pruritus it's first ensure and the the with burdening as symptoms. the frequency of mind versus when treating option of Bylvay HCPs will top the important drug for mind surgery, top reach as So be HCPs and

timing visits patients, on and What Another chronic is capture diagnosis patient each important and weight-based continually a is that is growth to of key treatment. either Bylvay given therapy. higher across annuity new a capture line months journey see represents straight not diseases is rare is others we with some or insight that that you patient seasonality, patient a than based

currently X have drug who important transition the in so metric in completion being now free commercial during of an are a which give how XXX. of with all numbers rollover is This example open-label are is of XXXX, patients a XX% number rollover program, advantage excellent XX%. of access launch, potential due the drug have We currently high to having future. approved to extension are what and reported as to keeping increase patient XX up provides XX at discontinuation we been Albireo quarter-over-quarter. speed the the trial patients launch their in that number that number And let as To transition the we it patients on patients patient these rollover following Assist around an in help the or the metric time who of available on reimbursement gaining numbers Moving patients to translate pointing potential as Bylvay in-house to and reimbursed low, of annuity we sales supports is significant and the initiations rate, reimbursed, until above Bylvay, In a demonstrate XX support of countries. we to patients. we seeing. Bylvay. are you QX, patients to period European reimburse fall the drugs believe commercial have had being the well rates the efficacy important multiple expected. why are end me since received from PEDFIC on visibility can next is in patient sales, lower-than-expected and This refill about strong The a on Rollover our QX, to waiting

we free one X reimbursement, we XX rollover in drug immediately will currently When have example, we become country, these patients. patients revenue-generating. For achieve PEDFIC and expect XX patients

the a immediately banked will different revenue-generating. a each While is be revenue-generating. Like countries the become the when of country patients on these step switches in become reimbursement country, all the EU number each gains as is of step and it U.S., in banked as significant the reimbursement change patients change of a patients

can about achieving global excited in see markets. is the why Flat U.S. prescribers you So metric these we reimbursement important unique in launch are

prescribers unique in Bylvay. who believe We prescribed have Bylvay have and XX

pleased level We slowly of of as XX% from penetration model expect this centers. is and prescriptions to this are with efficient the key time, over number grow with At are our coming same time. really

availability first impact education can on will PFIC. the PFIC sorry, availability pruritus option of teams PFIC. as the our The the drug -- forward, on focus Bylvay and drug awareness the continue have Bylvay of as of to treatment the and and of Moving first

continue we with prescribe are U.S., We the and outlook XXXX, we maximizing the as the prescriptions, for of on momentum Bylvay Bylvay increase types building In pruritus. broad are to launch physicians pleased focused all label, with to PFIC types all patients. of allows our annuity an which for

generating in wave we reach to really are Europe, the commercial reimbursement patients launch, the Overall, our to continued to adding pursuing prescribers. new continue prescriptions second multiple penetrating have remaining gain a bridging who focusing I'm our are drive patients. remaining As by drug and In and to seemingly on successfully date we in further concurrently market the as program, will bank geographic and patients our pricing with reimbursement. footprint. expanding stable convert targets actively with while HCPs by engagement by free we drug countries, we we we European happy into get

back the other hand me Now value Ron two to let it to drivers. cover

Ron Cooper

Great. Thanks, Pamela.

ASCERT. into number of but reimbursement pleased will I'm Now before that of jumping as gain sales is number important drivers, the I'm a the and we the I other on Pamela number the increasing, has patients is are patterns inventory know important value metrics, gone into most the in metric drug. confident that follow

of The and the of in the an with thrilled target second is announce pivotal driver trial our into diseases. for with with pediatric our trial to other original ASCERT of were value exceeded Albireo consistent enrollment expanding guidance. ASCERT completion Bylvay. study, The patients enrollment liver on focus expectations X Phase XX timing our XX syndrome We versus Alagille cholestatic in

are studies forward end commercially ability the speak and ASCERT the COVID of treatment recruiting of looking line the community We're top the to readout interest this during and challenges execute. does of in the results X to prescribing our really clinical and expect team by the option, Phase year. Given to available

for has have and U.S. our We In an opened Alagille access already been response outstanding. enrolled addition, Europe first patients in program syndrome. expanded the we and the

placebo-controlled PFIC Phase to be commercial with Also liver largest randomized, the or only cholestatic BOLD worldwide double-blind, our frame. over study, approval number from syndrome. drug Atresia the over on time is Biliary than Alagille would access disease launch placebo build both track is XXX Atresia that X sufficient FDA EMA study the randomized X-year have from Bylvay patients early with Biliary and standard As a of and combined. is the PFIC, we achieve is for time into to more a studied the which in patients significant approval. and analogy BOLD study pediatric have gold of roll the program confirmed ASCERT patients a for and expect study we by

on sales us and approvals Biliary top with keeping $X We year, X,XXX pieces readout for in Alagille pieces guidance PFIC, of data track the approximately XXXX. a X,XXX second and exceed expect project billion reach the enrollment in we to Global in to announce this confident achieving in of decade. completion this line to and half Atresia,

early of one-of-a-kind models, development. AXXXX AXXXX and clinical and And systemic the The in available unique in is demonstrates clearly inhibitor the commercially high ASBT development two value that from different assets, IBAT only third it preclinical in AXXXX first driver inhibitors. our world's AXXXX. bioavailable is is our

And X X study, of by Phase disease in the we study systemic year. excellent tolerability. liver exposure good end a in Phase adult anticipate a AXXXX starting an the and Additionally, demonstrates

NTCP inhibitor is potency the with injections. oral have only also AXXXX to engagement, of which NTCP of burden daily but profile the Development of subcu target available world's AXXXX, and without We similar the NTCP inhibitor. daily and tracking commercially is the first

and to X we've by end or excellent completed therapeutic combination expected concerns the of for component year plan unique be B rodent the a of with for treatment with AXXXX proving hepatitis no of study NTCP studies tox the to Beyond a D. finds Phase advance it dose. intent that, We the a into margins of

the products have capabilities the interest diseases. garnered potential and assets We larger the both and the strategic plans the At in rare have to more same AXXXX diseases. or time, AXXXX with for to both develop develop

quarter. over commitments So to development for to associated we're to breakdown the with three our financials first Simon of and side deliver through both overall, business. against the revenue the it commercial With you the drivers, on hand take that, continuing and Simon? value I'll

Simon Harford

Ron. Thanks,

U.S. summarize product revenue. $X.X our of for product and with results net million the the million reported million Bylvay for international XXXX. $X.X me QX Let revenue in quarter was financial net $X.X

from to the As we destocking of going in lower revenue this initial inventory the the levels of quarter. The expected year-end is forward. end standard in growth inventory QX, net due March, reflected QX said earnings launch prior revenue however, on reflects call reported Bylvay net we levels, for early demand to that than XXXX quarter, be product anticipated and product reported

XX% initiation growth As And trajectory the growth on Pamela QX. gives in this for patients confidence. quarter-on-quarter we great drug us had mentioned, of commercial revenue-generating

reported certain quality costs increase which were products now further launches in the As on European of EA headcount We'll care a visibility result, revenue anticipate Royalty partners. know, for current once as product royalty was to of of we from we with timing related XXXX, $X.X markets. increase was revenue and for in million. revenue in chronic revenue $X.X product of revenue. PFIC included to million materials QX, expensed on $XX are higher to material of first $X first of The market costs health million net no cost Pharma million following for aligned a approval last $X.X treatment to million the to minimum Elobixibat the constipation, product of update Cost you prior compared builder of passed quarter full opportunity. the Bylvay of sold is a royalty the better as you for XXXX estimated year, an for the manufacturing of approval. relates quarter were have year There

million the that expenses the SG&A of million the no the AXXXX were decrease million XXXX. attributable to compensation million. net the $X.XX global same increase of The XXXX, quarter our as during was expenses. cost or a loss activities. expenses and continue of in to were as to million to with related by we commercialization other quarter trials study The increase expansion for activities program first related year year. same a our period an last and is and $X for program support R&D due principally efforts. partially increase the to were year, XXXX activities $X.X last product quarter offset $XX.X of revenue first stock-based Bylvay, including well PFIC to Given expenses the and a of headcount increase Bylvay there and an $XX.X activities, to million to Bylvay our last compared The approved was was year, first we continue clinical in Net in loss to million. X and for in R&D headcount this of compared $XX.X was QX compared the preclinical $XX.X quarter in sales expenses third of expenses increase of Phase force share related and as million expenses, ongoing costs $XX.X increase personnel preclinical loss related for as personnel program or for $XX.X in of quarter of per quarter share of loss a $X.XX increase per including

of million at end million and XX, $XXX.X the had versus March cash December XXXX. the of equivalents cash of As company $XXX.X

upon cash that into current last We is XXXX to projections. our based expense sufficient and revenue our are guidance reiterating current

So remarks. turn me back over with let to Ron closing the call that, for

Ron Cooper

Thanks, Simon.

aware on would annuity we ahead be at expectations. are stronger clinical Clinical time week, of capturing are more for commercialization we this patients, Every from We a track stronger trials and creating we're standpoint. and a or growth. thought

$X to us key build make liver a advance our for to billion drug. As cholestatic stability to disease PFIC plans drug we product, pediatric the leading

need back the X estimated accomplish to world of our this by Phase the cholestatic on midterm our company as with near-term into pediatric X,XXX We $X a reach our X a very end time Biliary aspiration thank everybody to have business. expect first-in-class providing for sufficient for billion decade. first of on growth also countries, It's the base position, studies. term space, focused and And us in the Albireo by in and to growth. of method We're of then to and With syndrome into opportunity, into financial strong XXX,XXX first-to-market patients product for of We expand patients our building end pediatric advance Atresia stay the the Q&A. use portfolio Europe of patients build time tremendous exclusivity patent by number the to continue will call we AXXXX to patient around AXXXX drivers. we a all us extension joining pleased pleased by We quarter-by-quarter exciting in only of X,XXX this XXXX humans beyond giving and we'll proof-of-concept this Alagille us to a granted and our to year. now and the for plan liver open the the study are Operator? and Phase for

Operator

will Our the & is go from time, a At Baral Cowen you. first session. with Instructions] [Operator Thank be Please this of we Ritu line question conducting question-and-answer Co. ahead.

Ritu Baral

next the launches Good I taking the boluses? what the on some client. from And afternoon, Can and beyond have quarters? patient a a little you around And are also, think your levels predicted estimated that trigger in questions. inventory could for very a quick forward you will or follow-up of these then EU guys. bit U.K. question Thanks comment those whether drop current

Ron Cooper

Okay. question and talk Simon, the you can new the launches. Thank Ritu. take you, you don't Pamela, about inventory Why

Simon Harford

there talked now But about QX. is buildup forward. sort going Ritu. was Sure. we reflect much to in some right Suffice Hi, growth levels standard very that it current that the anticipated we of in levels of say terms inventory destocking where QX, in of are for have

talking don't inventory forward the through uptake, you launch during was that frankly, initial anticipate we're really going that So about period. and

revenue reported going in see forward pretty demand? So should accurately what you reflect

Pamela Stephenson

we submitted U.K. we and reimbursement launches, the XX another hi. reimbursement have countries. Ritu, in On dossiers regarding And in question as have European in Germany know, your you And the

in are we those and the pricing X European reimbursement. update we in and So big half EU year. look continue go you active focus We'll to once forward online and gain coming of to we second on negotiations countries, we'll beyond, countries key as the we and

Ritu Baral

helpful somebody Alagille. just models. patient your Thank And enough. contrast I but numbers, Fair for thought maybe pricing price and basis, to it about just Just the be Alagille? can't Has relative asking on a understand general to you in you average PFIC. then moving net exact of quickly a how you. work would think on give compares will

Ron Cooper

Thanks, little for early I'm bit a Ritu. us. Yes, probably

off, study overenrolled see have to I super then what and to this major from what the we're out readout. say we to regulators the what Phase have X reading a to excited readout we ASCERT think, says see that year label and the data have first a have Obviously, perspective.

we drive a be think quarter a we'll pretty perspective, feel confident So a that from or price that will that's price. where we are in competitive but we

Ritu Baral

Got it. you. Thank

Operator

Thank you.

Please Our ahead. the next from Yang go of Jefferies. is question with Eun line

Eun Yang

Thank you.

XXX given So who liver those in eligible you good are And [indiscernible]. more PFIC, it of quickly. -- not literal And say same only the some in the are why capturing isn't when patients, that terms approved eligible patients there having patients else U.S. XXX odevixibat you drug, are the patients transplant the at time liver function

Ron Cooper

little had but your and bit, chopped off we around some patients. uptake see line think the of I sort available So how questions you a Ritu,

focused patients. have do think So we're the that diagnosed is take lot right disease are we What U.S. get And a we live, I a to we rare patients, in in, as Europe, the global And we're the and we're our in that I surgery patients and in in prevalence have out had available finding a with newly waiting. early gets market, to we planned. getting excited available that ineligible us what and and patients super we is going of patients this been and estimate globally. way are or it’s really is X,XXX medically to the that where the is patients, is now, believe particular, And market opportunity, that we there that that's the it U.S. think disease. patients And prevalence the both right, get that The of early we're are the are have we're patients Europe. our penetration in when banking and the reality start

find that is be to to group we get our that to getting as the Now we going urgency work patients, treat, really as to of not great next but much those manage. there's suburbs they're we're patients results. And actually

with thus delighted we're the So far. performance

Eun Yang

in Okay. And on then question the prior question on I on have syndrome follow-up a the Alagille pricing.

microgram kilogram up is in in starting are or XXX you the dose dosage the kilogram age What XX the PEDFIC, microgram the trial. So to going and XXX. with or

is way post the So a based those And this different. things. also is

syndrome, PFIC? of think potentially could higher than Xx pricing the you it Alagille do be So

Ron Cooper

see data Yes. to I have Again, the as regulators. we with have the we I said until think to Ritu, discussions and really wait we

we the from in that XX dosage, XXX first. agency with a right? the of a get recall to data to might XX, And we had with range XX dosage You PFIC finished And and the U.S. so U.S. we XXX. the have in

to regulators dosage at will we're the to from talk of we things. to there, all can manage have be. we pretty would then And but confident determine what look those We price, the

Eun Yang

Thank you.

Operator

you. Thank

line Please next of is the Our from Brian go ahead. Skorney with question Baird.

Brian Skorney

taking afternoon, questions. for the Hey, good guys. Thanks

there a of the lot inventory growth. in whatever is and XQ U.S. was drawdown uncertainty I dynamics XQ think in with the about

online to think were to would discuss you needs at U.K. being to achieve What two be So demand sort for about is. able would quarters? So a And think for sales growth looking the providing actual maybe contribution happen $XX million what qualitatively, Thanks. you U.S. versus the just that get the ex besides handle maybe what how Germany U.S. to U.S.? of actual to million $XX about that number? else and

Simon Harford

Brian, this Simon. afternoon, is Good

situation, end of terms the now much inventory through in the think the pretty of March. discussion we're I at

be really going mentioned I reported revenue about earlier, our talking closely aligned because demand inventory our as revenue. should forward, don't anticipate we So fairly with

to in going very PFIC might $XX you our to we there how the million, as out year of the a put is to minimum year. help minds think much forward progress through the decided opportunity we which of during full you So aligned guidance

maybe about million, the are which timing thing, point at feeling why a make quarter-on-quarter I this patient who you can sort few that should revenue XX% million, of time. in at then and on I of reimbursement growth is take QX indicating here is markets. from minimum then sort the other expect European at essentially only blocks And number, recognize of to think is, in the feel and patients pretty sort in or whereby you as countries. going there your in $XX develop annualize simple those in grow a you a difference, forward there be the is about in those million building the actually you generating of variable on revenue those the a into year. Yes, think, build here about just increase sort QX, situation models because that, good to and big people if project that And quite to had way roughly, growth, as of think that. the of if Germany. that we and it $XX you're $XX U.S. we nicely we're obviously, months we pretty top of you Then the good forward is helping forward in rest further have both of roll already of the we continuing is The quite question now you of and

little bit overall basis. So global gives of on a color that hopefully, a

Brian Skorney

you. thank Yes,

Ron Cooper

you. Thank

Operator

line go is from the Tim with ahead. question Please of next William Lugo Our Blair.

Unidentified Analyst

This for for Thanks guys. [ph] is Lockton Hey, Tim. questions. taking the on

Ron Cooper

ahead, Go Lockton.

Unidentified Analyst

guys you Yes. hear Can me?

Ron Cooper

we Now can.

Simon Harford

can, we Now yes.

Unidentified Analyst

Okay, great.

so, the it is it, if the about And key topic new a correct? coming not are your I sort that. hearing if like the others expectations you're you and not that a or that is and are identifying from you're or are they cutting then coming into in where second being prescriptions key heading launch I of clarification. of physicians patients? think aligning if just the But, in out And of centers. sounded Sorry field line at my but center. of was wondering are wondering with said a epidemiology, seeing XX% are on the just called about on of from what kind prescriber, prescribers Is from any

Ron Cooper

here. it's Hey, Ron

of reiterate, pretty estimates, around all, our was much what see the first from then are we centers. it at world. look as patients right? XX% coming PFIC we And to the of think say, we're there's So we our in field So key prescriptions X,XXX

So we're business about pleased not areas, really much about model our as that spending because targeted resource. is

centers. And biggest of pleased The so of some the coming that prescriptions. the we're from centers, we're the are rest getting from most smaller

Unidentified Analyst

Got it. Thanks.

Ron Cooper

Thanks, Lockton.

Operator

Thank you.

the from Securities. Argyrides is question Next Andreas line ahead. of with Wedbush Please go

Andreas Argyrides

Hello, questions. Thanks for good taking afternoon. my

approved as be discontinuation what rates is looking of free And might early Can you study has the will Alagille, launch to the you market? there for drug what of as then expected. when PFIC, is enrollment been you patients Thanks. are guide receiving for to kind no patients So driving this Also, as free the to at And are already on receiving seeing? drug? what percentage elaborate an in have us drug? remarks, mentioned longer when dynamics, patients your prepared but can you

Ron Cooper

Andreas free So about And speak discontinuation. the Pamela, you on I'll address why study. questions don't and allege drug

Pamela Stephenson

Right.

So expenses got those as for we we or of were mentioned, in XX% drug insured patients. reimbursed patients that QX were

are for are drug. we X that And few actively transition drugs, That's onto who on but patients working you question patients are paid of to so first the asked. sort a there those

the you what this with sharing is what I And not that expect other tell a fluid number. while small is you in rate that time, can has only seen launch. at would our we're discontinuation a second, the for a been disease line rare number we have On dynamic of is here which discontinuations,

Bylvay. these are They We patients some of -- who back off efficacy. family for continuing of on. beliefs really pleased overall, to sort deciding There's there's the are we're have really, who -- with trend. others of have on very humanistic coming come come therapy, But a with play. while And one-offs. discontinuations are or into none therapy those that number are And not some patients these sometimes are been

Ron Cooper

excited, and sites Great. recruit this on front, excited, able Thanks, has right? effectively team we're our in to and been study. able to time operate the Alagille been super study guidance, on working COVID I to we're Pamela. up all, that with the think of but our our able crazy the has investigators, first been going get actually over have recruit and environment

this patients number medical the need the of there, speaks the and analogy, out that patients think nature I to the treatment heterogeneous options. for unmet of need

to then, X forward Phase of later this syndrome. year. course, of a readout subsequent in allege looking commercialization bile filing major we're and So And

Andreas Argyrides

Got it, thanks.

Ron Cooper

Andreas. Thanks,

Operator

you. Thank

Our of question Arce go is Ed Wainwright the line Please ahead. Co. H.C. & next with from

Ed Arce

everyone. Thanks okay? Can questions. taking for my Hi, hear me, you

Ron Cooper

hear can thank and louder clear, We Ed, you. you

Ed Arce

Ron. Great,

few a questions from me. So

the I year Firstly, there. color for appreciate you extra revenue Bylvay the that provided and the guidance minimum

Ron Cooper

quarter follow-ups. just cadence overall as level? now couple normal the XXXX next X.X% Wondering, -- quarter a around through you've the just then at as with I and question X% to Simon? of million through about levels, or above though, is if, if think that net this year, remaining flow this in quarters that And work of we looking versus a destocked sales to wondering as $X have

Simon Harford

the Yes, reality is sort of of the Ed, because inventory. that were we the fact was that lowest clearly is in quarter QX that Simon. this drawdown reporting

proxy expect to are and think what and are continuing when you is generating revenue forward, a more patients good going it's demand a build. quarter-by-quarter, would the see building basis, currently on to So I on obviously, who

demand. quarters would next is quarter I about think way in quarter the should remaining each on be So building three terms the of the

the expect the building way be QX answer of would patients you just are by QX, time. definition So over to the than is higher yes,

Ron Cooper

And underway. just Pamela reimbursement stated and position we dozen have remind pricing Europe you, I in a would as

patients drug XXX have We on are rollovers. that potential are that

which be So we've unlike thus right, growth, what experienced growth, relatively far, has are of going are to have which step we spikes going changes. been linear to

that Pamela in country flip example, that as the XX And so patients will one that right, outlined over.

well. like countries that have We other as

think continue So base that Simon, grow. as we're going see as year, we to to about said, the

European you but going too. countries, then and going in patients way. in they're We are the linear be add going to a nice not step layer to to come in new and They're U.S. in some Germany where

Ed Arce

Right.

Fair Okay. enough.

I this come restocking of be aware average just March, Thank of any addition, there wondering as we just adjustment growth if through are could worked In you. thinking, And share in the already noted, you then other thinking end up? that the to I issue, launch. what as headwinds net work the the model, or you've should through through by to so far could is gross sales

Ron Cooper

gross I'll about net speak just you address and that… don't Why to side then

Simon Harford

Yes, sure.

patients in of insurance it as net, Medicaid Those driver In report gross is patients would revenue. patients. we Medicaid I mix what commercial U.S., Ed, terms the of the sort patients say because financials of of obviously, is can don't between net a report we expect have you But and biggest our to kind in mandatory. paid

it's tend than think XX% I commercial payers overall. be that discount to less obviously

less that for that for in but So more mix overall range of Medicaid payers, than commercial say of really of percent the that, it's can't sort patients. -- drives XX-odd I sort

Ron Cooper

your see question, lots add to going drive of And revenue additional forward. opportunity to we

experienced the other what there we've are additional launch. of no beginning at So than headwinds

Ed Arce

again. it. Got Thanks,

Ron Cooper

Thank you, Ed.

Operator

Thank you. back I turn the Ron to reached remarks. to closing the gentlemen, would Ladies question-and-answer And Cooper and call end for we like the of have session.

Ron Cooper

you, of all thank updated with every families continued operator, each patients your to of community. as execute Albireo's And attending try today's their support. disease and for all we organization's and liver and our you plan and for and continue one thank as conference provide innovation I'm to for to the vision and deliver of to our liver you to advance call. keep hope employees entire commitment, proud Thank thank ability

Operator

today's concludes conference. This you. Thank

your you may for lines Thank your at time. participation. this disconnect You

Albireo Pharma (ALBO) 17 May 222022 Q1 Earnings call transcript